Skip to content

Study · Randomized controlled trial · n = 302 · 1999

4 results

A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis.

Uhl W, Büchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W

Gut1 Jul 1999Cited by 117 (Europe PMC)

PMID10369711 (opens in a new tab)PMCIDPMC1727562 (opens in a new tab)DOI10.1136/gut.45.1.97 (opens in a new tab)PepBankPUB-10369711
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In moderate to severe acute pancreatitis, mortality was 15% with octreotide 100 microg versus 16% with placebo, without a significant difference.

    In plain wordsIn acute pancreatitis, mortality was 15% with octreotide 100 microg versus 16% with placebo, without a significant difference.

    Peptide
    Octreotide
    Outcome
    DecreaseMortality at lower dose
    Study

    n = 302

    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    100 microg three times daily · subcutaneous · seven daysAs given in this study (human).

    Measurements

    Mortality
    16%
    placebo group
    Mortality
    15%
    octreotide 100 microg group

    Source sentences

    Summary
    An intent to treat analysis of all 302 patients revealed no significant differences among treatment groups with respect to mortality (P: 16%; O1: 15%; O2: 12%), the rate of newly developed complications, the duration of pain, surgical interventions, or the length of the hospital stay.
    2 context sentences
    Summary · context
    302 patients from 32 hospitals, fulfilling the criteria for moderate to severe acute pancreatitis within 96 hours of the onset of symptoms, were randomly assigned to one of three treatment groups:
    Summary · context
    group P (n=103) received placebo, while groups O1 (n=98) and O2 (n=101) received 100 and 200 microg of octreotide, respectively, by subcutaneous injection three times daily for seven days.
  2. 02HumanRandomized controlled trialSafety outcome

    In moderate to severe acute pancreatitis, mortality was 12% with octreotide 200 microg versus 16% with placebo, without a significant difference.

    In plain wordsIn acute pancreatitis, mortality was 12% with octreotide 200 microg versus 16% with placebo, without a significant difference.

    Peptide
    Octreotide
    Outcome
    DecreaseMortality at higher dose
    Study

    n = 302

    Comparator
    Placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    200 microg three times daily · subcutaneous · seven daysAs given in this study (human).

    Measurements

    Mortality
    16%
    placebo group
    Mortality
    12%
    octreotide 200 microg group

    Source sentences

    Summary
    An intent to treat analysis of all 302 patients revealed no significant differences among treatment groups with respect to mortality (P: 16%; O1: 15%; O2: 12%), the rate of newly developed complications, the duration of pain, surgical interventions, or the length of the hospital stay.
    2 context sentences
    Summary · context
    302 patients from 32 hospitals, fulfilling the criteria for moderate to severe acute pancreatitis within 96 hours of the onset of symptoms, were randomly assigned to one of three treatment groups:
    Summary · context
    group P (n=103) received placebo, while groups O1 (n=98) and O2 (n=101) received 100 and 200 microg of octreotide, respectively, by subcutaneous injection three times daily for seven days.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acute pancreatitis, octreotide groups showed no significant differences in new complications, pain duration, surgery, or hospital stay versus other groups.

    In plain wordsIn acute pancreatitis, octreotide groups did not differ significantly from other groups in complications, pain duration, surgery, or hospital stay.

    Peptide
    Octreotide
    Outcome
    No significant changeComplications, pain duration, surgery and hospital stay
    Study

    n = 302

    Comparator
    Other randomized treatment groups
    Outcome group
    Pancreatitis Outcomes · Gastrointestinal
    Studied dose
    100 or 200 microg three times daily · subcutaneous · seven daysAs given in this study (human).

    Source sentences

    Summary
    An intent to treat analysis of all 302 patients revealed no significant differences among treatment groups with respect to mortality (P: 16%; O1: 15%; O2: 12%), the rate of newly developed complications, the duration of pain, surgical interventions, or the length of the hospital stay.
    2 context sentences
    Summary · context
    302 patients from 32 hospitals, fulfilling the criteria for moderate to severe acute pancreatitis within 96 hours of the onset of symptoms, were randomly assigned to one of three treatment groups:
    Summary · context
    group P (n=103) received placebo, while groups O1 (n=98) and O2 (n=101) received 100 and 200 microg of octreotide, respectively, by subcutaneous injection three times daily for seven days.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In acute pancreatitis, the valid-for-efficacy analysis also found no significant differences among octreotide and placebo groups.

    In plain wordsIn acute pancreatitis, the additional efficacy analysis found no significant differences among octreotide and placebo groups.

    Peptide
    Octreotide
    Outcome
    No significant changeValid-for-efficacy analysis
    Study

    n = 251

    Comparator
    Other randomized treatment groups
    Outcome group
    Pancreatitis Outcomes · Gastrointestinal
    Studied dose
    100 or 200 microg three times daily · subcutaneous · seven daysAs given in this study (human).

    Source sentences

    Summary
    A valid for efficacy analysis (251 patients) also revealed no significant differences.
    2 context sentences
    Summary · context
    302 patients from 32 hospitals, fulfilling the criteria for moderate to severe acute pancreatitis within 96 hours of the onset of symptoms, were randomly assigned to one of three treatment groups:
    Summary · context
    group P (n=103) received placebo, while groups O1 (n=98) and O2 (n=101) received 100 and 200 microg of octreotide, respectively, by subcutaneous injection three times daily for seven days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.